BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 30488367)

  • 1. Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study.
    An Y; Zhou Y; Bi L; Liu B; Wang H; Lin J; Xu D; Wang M; Zhang J; Wang Y; An Y; Zhu P; Xie R; Zhang Z; Mei Y; Liu X; Deng X; Yao Z; Zhang Z; Wang Y; Xiao W; Shen H; Yang X; Xu H; Yu F; Wang G; Lu X; Li Y; Li Y; Zuo X; Li Y; Liu Y; Zhao Y; Guo J; Sun L; Zhao M; Li Z
    Clin Rheumatol; 2019 Apr; 38(4):1047-1054. PubMed ID: 30488367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.
    Zhang M; Qi C; Zha Y; Chen J; Luo P; Wang L; Sun Z; Wan J; Xing C; Wang S; Jiang G; Sun M; Chen Q; Chen J; Li D; Guan T; Ni Z
    Clin Rheumatol; 2019 Mar; 38(3):859-867. PubMed ID: 30426311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.
    Chan TM; Li FK; Tang CS; Wong RW; Fang GX; Ji YL; Lau CS; Wong AK; Tong MK; Chan KW; Lai KN
    N Engl J Med; 2000 Oct; 343(16):1156-62. PubMed ID: 11036121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
    Ginzler EM; Dooley MA; Aranow C; Kim MY; Buyon J; Merrill JT; Petri M; Gilkeson GS; Wallace DJ; Weisman MH; Appel GB
    N Engl J Med; 2005 Nov; 353(21):2219-28. PubMed ID: 16306519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
    Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.
    Liu Z; Zhang H; Liu Z; Xing C; Fu P; Ni Z; Chen J; Lin H; Liu F; He Y; He Y; Miao L; Chen N; Li Y; Gu Y; Shi W; Hu W; Liu Z; Bao H; Zeng C; Zhou M
    Ann Intern Med; 2015 Jan; 162(1):18-26. PubMed ID: 25383558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential therapies for proliferative lupus nephritis.
    Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
    N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment for lupus nephritis.
    Henderson L; Masson P; Craig JC; Flanc RS; Roberts MA; Strippoli GF; Webster AC
    Cochrane Database Syst Rev; 2012 Dec; 12():CD002922. PubMed ID: 23235592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.
    Ginzler EM; Wofsy D; Isenberg D; Gordon C; Lisk L; Dooley MA;
    Arthritis Rheum; 2010 Jan; 62(1):211-21. PubMed ID: 20039429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.
    Houssiau FA; D'Cruz D; Sangle S; Remy P; Vasconcelos C; Petrovic R; Fiehn C; de Ramon Garrido E; Gilboe IM; Tektonidou M; Blockmans D; Ravelingien I; le Guern V; Depresseux G; Guillevin L; Cervera R;
    Ann Rheum Dis; 2010 Dec; 69(12):2083-9. PubMed ID: 20833738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis.
    Tian SY; Feldman BM; Beyene J; Brown PE; Uleryk EM; Silverman ED
    J Rheumatol; 2014 Oct; 41(10):1998-2007. PubMed ID: 25225281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis.
    Baskin E; Ozen S; Cakar N; Bayrakci US; Demirkaya E; Bakkaloglu A
    Pediatr Nephrol; 2010 Jan; 25(1):111-7. PubMed ID: 19727839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
    Sedhain A; Hada R; Agrawal RK; Bhattarai GR; Baral A
    BMC Nephrol; 2018 Jul; 19(1):175. PubMed ID: 29996800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
    Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A
    Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up.
    Fu Q; Wu C; Dai M; Wang S; Xu J; Dai L; Li Z; He L; Zhu X; Sun L; Lu L; Bao C
    Ann Rheum Dis; 2022 Nov; 81(11):1549-1555. PubMed ID: 35788493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy.
    Gul H; Mushtaq MS; Salim B; Samreen S; Nasim A; Khan M
    J Ayub Med Coll Abbottabad; 2020; 32(4):454-458. PubMed ID: 33225643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
    Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
    Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
    Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
    Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.
    Cooper JC; Rouster-Stevens K; Wright TB; Hsu JJ; Klein-Gitelman MS; Ardoin SP; Schanberg LE; Brunner HI; Eberhard BA; Wagner-Weiner L; Mehta J; Haines K; McCurdy DK; Phillips TA; Huang Z; von Scheven E;
    Pediatr Rheumatol Online J; 2018 Oct; 16(1):65. PubMed ID: 30348175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.